YH32367-101
14 Sep 2023
Trial Summary
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Acronym:
YH32367-101
ACTRN/NCT /ethics:
NCT05523947
Scientific title:
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Sponsor / Cooperative group:
Yuhan Corporation
Trial & Patient Characteristics
| Cancer Type | HER2-Positive Solid Tumor |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I & Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | - |
| Anticipated Start Date | 2022-08-26 |
| Anticipated End Date | 2026-10-06 |
Participating Hospitals
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.Oriley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Ganessan Kichenadasse |
| Recruitment Status | Recruiting |